Home / Market News / $RCKT
benzinga Corporate Catalyst Impact 55/100 ● positive

Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral, Raises Price Target to $4

Oct 8, 2026, 10:09 AM UTC · Primary ticker $RCKT

Goldman Sachs has upgraded Rocket Pharmaceuticals from a 'Sell' to a 'Neutral' rating and increased its price target from $3 to $4. This indicates a slightly more positive outlook from the analyst, which could lead to a modest short-term positive reaction for RCKT shares.

Goldman Sachs analyst Richard Law upgraded Rocket Pharmaceuticals (RCKT) from a 'Sell' to a 'Neutral' rating and raised the price target from $3 to $4. This change in analyst sentiment is generally viewed positively by the market, as it suggests a reduced downside risk and potentially some upside. For traders, this could lead to a short-term bump in RCKT's stock price as investors react to the improved outlook. While not a major catalyst like a drug approval or clinical trial result, an analyst upgrade from a prominent firm like Goldman Sachs can influence investor perception and trading activity. The long-term implications depend on the company's fundamental performance and future developments, but in the short term, it presents a potential opportunity for those looking for a modest positive swing.

$RCKT positive Analyst upgrade and price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.